Pervin Topçuoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pervin Topçuoğlu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Selami Koçak Toprak
Ankara University Faculty of Medicine, Department of Hematology, Ankara, Türkiye
7 shared publications - Sinem Civriz Bozdağ
Ankara University Faculty of Medicine, Department of Hematology, Ankara, Türkiye
7 shared publications - Guldane Cengiz Seval
Department of Hematology, Faculty of Medicine, Ankara University, Ankara, Turkey
6 shared publications - Gunhan Gurman
Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
5 shared publications - Meltem Kurt Yüksel
Ankara University Faculty of Medicine, Department of Hematology, Ankara, Türkiye
5 shared publications - Meral Beksac
Istinye University, Ankara, Turkey
4 shared publications
Latest Publications
- 28 April 2026
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 10 (1) , 18-23
Kronik Miyeloid Löseminin İlk Sıra Tedavisinde Özgün ve Jenerik İmatinib Formülasyonlarının Karşılaştırılması: Gerçek Yaşam Verileri
- 28 April 2026
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 10 (1) , 18-23
Kronik Miyeloid Löseminin İlk Sıra Tedavisinde Özgün ve Jenerik İmatinib Formülasyonlarının Karşılaştırılması: Gerçek Yaşam Verileri
- Open Access
- 26 December 2023
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 71 (4) , 420-427
A patient with widespread skin lesions presenting with massive pleural effusion
Mycosis fungoides is the most commonly seen type of cutaneous T-cell lymphoproliferative disease. While mycosis fungoides is linked to an increased risk of developing secondary malignancies, the occurrence of B- cell-originated disease in association with it is exceedingly rare. A 66-year-old male with persistent papillomatous skin eruption was admitted due to dyspnea. Chest X-ray, positron emission tomography, and chest computed tomography revealed axillary and mediastinal lymph node enlargement and right lower pulmonary lobe infiltration along with right-sided massive pleural effusion. Histological and immunohistochemical findings of pleural biopsy and axillary lymph nodes suggested a diagnosis of pulmonary extranodal marginal zone lymphoma. Skin biopsies from the abdomen, chest, and legs revealed CD4/CD8 double-positive patch stage of mycosis fungoides. After completing six cycles of chemotherapy, complete remission of lymphoma was achieved, with the skin eruptions remaining unchanged. Herein, the authors present a unique case of concomitant diagnoses of mycosis fungoides and marginal zone B-cell lymphoma of the respiratory system to emphasize the importance of careful evaluation of each finding.
- 26 December 2023
- Published by Bilimsel Tip Publishing House in Tuberk Toraks
- Vol. 71 (4) , 420-427
Open AccessA patient with widespread skin lesions presenting with massive pleural effusion
Mycosis fungoides is the most commonly seen type of cutaneous T-cell lymphoproliferative disease. While mycosis fungoides is linked to an increased risk of developing secondary malignancies, the occurrence of B- cell-originated disease in association with it is exceedingly rare. A 66-year-old male with persistent papillomatous skin eruption was admitted due to dyspnea. Chest X-ray, positron emission tomography, and chest computed tomography revealed axillary and mediastinal lymph node enlargement and right lower pulmonary lobe infiltration along with right-sided massive pleural effusion. Histological and immunohistochemical findings of pleural biopsy and axillary lymph nodes suggested a diagnosis of pulmonary extranodal marginal zone lymphoma. Skin biopsies from the abdomen, chest, and legs revealed CD4/CD8 double-positive patch stage of mycosis fungoides. After completing six cycles of chemotherapy, complete remission of lymphoma was achieved, with the skin eruptions remaining unchanged. Herein, the authors present a unique case of concomitant diagnoses of mycosis fungoides and marginal zone B-cell lymphoma of the respiratory system to emphasize the importance of careful evaluation of each finding.
- Open Access
- 10 May 2023
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 40 (3) , 197-204
Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center
Allogeneic hematopoietic stem cell transplantation is a well-established approach for patients diagnosed with primary myelofibrosis and remains the only potentially curative treatment. To present the overall outcome of patients with myelofibrosis treated with allogeneic hematopoietic stem cell transplantation. A retrospective cross-sectional study. This study is a retrospective analysis of 26 consecutive patients with primary myelofibrosis who underwent transplantation at our center between January 2002 and January 2022. Disease and transplant variables contributing to outcomes were analyzed. The median age at the time of transplantation was 52.5 (range, 32-63) years and the median time from diagnosis to allogeneic hematopoietic stem cell transplantation was 25 (range, 3.1-156.8) months. Myeloablative conditioning and reduced-intensity conditioning regimens were used in 8 (30.8%) and 18 (69.2%) transplantations, respectively. Neutrophil and platelet engraftment was achieved in 23 patients at a median follow-up of 21.2 months (range, 12 days to 234.8 months). Primary graft failure occurred in 1 of 23 patients (4.3%). Neutrophil and platelet engraftment occurred at a median of 16 (range, 12-39) days and 20 (range, 11-78) days, respectively. Acute graft-versus-host disease was seen in 11 of 22 patients engrafted allografts, of which 7 (31.8%) were grade 3-4 acute graft-versus-host disease. Eight patients (36.4%) developed chronic graft-versus-host disease, and three cases were extensive. Four patients (19%) relapsed after a median of 5.5 months, and three patients received donor lymphocyte infusion. The 3-year overall survival rate of the entire study population was 46.2%. The median overall survival was not reached in the myeloablative conditioning group; however, it was 11.9 months in the reduced-intensity conditioning group (p =0.3). According to the donor graft source, the median overall survival was 0.73 months in mismatched unrelated graft recipients, 12 months in matched sibling donors, and not reached in matched unrelated graft recipients (p = 0.03). The 3-year progression-free survival rate of patients who survived > 100 days was 74.7%. The effect of JAK-2 status, graft source, conditioning regimen or dynamic international prognostic scoring system on progression-free survival was not statistically significant. Given the poor prognosis of non-transplant recipients and the lack of non-transplant curative approaches, our results support the consideration of allogeneic hematopoietic stem cell transplantation for eligible patients with primary myelofibrosis.
- 10 May 2023
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 40 (3) , 197-204
Open AccessAllogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis: A 20-year Experience in a Single Center
Allogeneic hematopoietic stem cell transplantation is a well-established approach for patients diagnosed with primary myelofibrosis and remains the only potentially curative treatment. To present the overall outcome of patients with myelofibrosis treated with allogeneic hematopoietic stem cell transplantation. A retrospective cross-sectional study. This study is a retrospective analysis of 26 consecutive patients with primary myelofibrosis who underwent transplantation at our center between January 2002 and January 2022. Disease and transplant variables contributing to outcomes were analyzed. The median age at the time of transplantation was 52.5 (range, 32-63) years and the median time from diagnosis to allogeneic hematopoietic stem cell transplantation was 25 (range, 3.1-156.8) months. Myeloablative conditioning and reduced-intensity conditioning regimens were used in 8 (30.8%) and 18 (69.2%) transplantations, respectively. Neutrophil and platelet engraftment was achieved in 23 patients at a median follow-up of 21.2 months (range, 12 days to 234.8 months). Primary graft failure occurred in 1 of 23 patients (4.3%). Neutrophil and platelet engraftment occurred at a median of 16 (range, 12-39) days and 20 (range, 11-78) days, respectively. Acute graft-versus-host disease was seen in 11 of 22 patients engrafted allografts, of which 7 (31.8%) were grade 3-4 acute graft-versus-host disease. Eight patients (36.4%) developed chronic graft-versus-host disease, and three cases were extensive. Four patients (19%) relapsed after a median of 5.5 months, and three patients received donor lymphocyte infusion. The 3-year overall survival rate of the entire study population was 46.2%. The median overall survival was not reached in the myeloablative conditioning group; however, it was 11.9 months in the reduced-intensity conditioning group (p =0.3). According to the donor graft source, the median overall survival was 0.73 months in mismatched unrelated graft recipients, 12 months in matched sibling donors, and not reached in matched unrelated graft recipients (p = 0.03). The 3-year progression-free survival rate of patients who survived > 100 days was 74.7%. The effect of JAK-2 status, graft source, conditioning regimen or dynamic international prognostic scoring system on progression-free survival was not statistically significant. Given the poor prognosis of non-transplant recipients and the lack of non-transplant curative approaches, our results support the consideration of allogeneic hematopoietic stem cell transplantation for eligible patients with primary myelofibrosis.
- 17 December 2021
- Published by Galenos Yayinevi in Journal of Ankara University Faculty of Medicine
- Vol. 74 (3) , 337-342
The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation
- 17 December 2021
- Published by Galenos Yayinevi in Journal of Ankara University Faculty of Medicine
- Vol. 74 (3) , 337-342
The Influence of ATG on the Outcomes of Patients With AML at the Time of Unrelated Donor Transplantation
- 19 August 2021
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 5 (1) , 16-20
Allogeneic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: A Single Center Experience
- 19 August 2021
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 5 (1) , 16-20
Allogeneic Stem Cell Transplantation for Chronic Myelomonocytic Leukemia: A Single Center Experience
- 19 August 2021
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 5 (1) , 1-4
Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience
- 19 August 2021
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 5 (1) , 1-4
Brentuksimab Vedotin Treatment in Relaps Refractory Hodgkin Lymphoma: A Single Center Experience
- 1 August 2020
- Published by Galenos Yayinevi in Journal of Ankara University Faculty of Medicine
- Vol. 73 (2) , 113-117
Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome
- 1 August 2020
- Published by Galenos Yayinevi in Journal of Ankara University Faculty of Medicine
- Vol. 73 (2) , 113-117
Allogeneic Stem Cell Transplantation in Myelodysplastic Syndrome
- 17 June 2020
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 4 (2) , 23-27
Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis
- 17 June 2020
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 4 (2) , 23-27
Safety and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Mycosis Fungoides and Sezary Syndrome: A 7-year Tertiary Center Analysis